Skip to main content

Advertisement

Table 1 Clinical and tumor characteristics, therapeutic regimens, and clinical response in 355 cervical cancer patients

From: Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy

Characteristics Number (%)
Histopathology  
 Squamous cell carcinoma 209 (58.8)
 Adenocarcinoma 120 (34.0)
 Adenosquamous carcinoma 15 (4.1)
 Serous carcinoma 1 (0.3)
 Clear cell carcinoma 3 (0.8)
 Mixed types 1 (0.3)
 Undifferentiated carcinoma 5 (1.4)
 Adenosarcoma 1 (0.3)
Initial FIGO stage  
 IA 6 (1.7)
 IB 53 (14.9)
 IIA 15 (4.2)
 IIB 90 (25.4)
 IIIA 1 (0.3)
 IIIB 127 (35.8)
 IVA 9 (2.5)
 IVB 50 (14.1)
 Inadvertent hysterectomy 3 (0.8)
 No data 1 (0.3)
Primary treatment  
 Radiotherapy 42 (11.8)
 Concurrent chemoradiotherapy 209 (58.9)
 Surgery 42 (11.8)
 Chemotherapy 62 (17.5)
Disease sites before chemotherapy initiation  
 Locoregional 138 (38.9)
 Distant 90 (25.4)
 Both 127 (35.8)
Chemotherapeutic agents  
 Platinumsa + Paclitaxel 255 (71.8)
 Platinumsa + Fluorouracil based 27 (7.6)
 Cisplatin + Topotecan 10 (2.8)
 Cisplatin + Mitomycin 13 (3.7)
 Cisplatin + Ifosfamide 12 (3.4)
 Cisplatin + Gemcitabine 1 (0.3)
 Single drugsb 37 (10.4)
Response to treatment  
 Complete response 79 (22.3)
 Partial response 54 (15.2)
 Stable of disease 108 (30.4)
 Disease progression 114 (32.1)
Recurrent or persistent disease  
 No recurrence 35 (9.9)
 Recurrence after complete response 44 (12.4)
 Persistent disease 276 (77.7)
Last contact outcomes  
 Alive without disease 39 (11.0)
 Alive with disease 204 (57.5)
 Death without disease 0
 Death with disease 112 (31.5)
  1. FIGO the International Federation of Gynecology and Obstetrics
  2. aPlatinums include either Cisplatin or Carboplatin
  3. bSingle agents compose of Cisplatin, Carboplatoin, Mitomycin C, Paclitaxel, Gemcitabine, Ifosfamide